Search Results

Featured Stories

Toggle

Showing 10 of 308 results

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Four posters examine the long-term efficacy, safety, and tolerability of AUSTEDO in patients with tardive dyskinesia and a review of clinical outcome measures in schizophrenia TEL AVIV, Israel &...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

19 presentations will examine long-term and real-world AJOVY data as well as AUSTEDO safety and adherence data TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc.,...

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

In vitro findings suggest specific classifications for calcitonin gene-related peptide (CGRP) pathway-based therapeutics based on mechanisms TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical...

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability...

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release S

Study met its primary efficacy endpoint of delaying time to relapse TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext:...

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY

Analysis assessed migraine days at the beginning and end of quarterly and monthly dosing intervals TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) toda...

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disopro

  TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the availability of t...

First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Publish

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly AJOVY® (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Eval

Additional data to be presented examining the safety and tolerability of AUSTEDO during periods of titration and maintenance